Keyword Analysis & Research: catalyst pharmaceuticals


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
catalyst pharmaceuticals0.150.5676910024
catalyst1.81828118
pharmaceuticals0.490.71102715

Keyword Research: People who searched catalyst pharmaceuticals also searched

Keyword CPC PCC Volume Score
catalyst pharmaceuticals0.121526648

Search Results related to catalyst pharmaceuticals on Search Engine

  • Catalyst: A Biopharmaceutical Company Focused on Rare Diseases

    catalystpharma.com

    https://catalystpharma.com/

    WEBThe innovation behind a breakthrough. Our company is committed to developing novel, safe, and efficacious therapies to improve the lives of people with rare diseases.

    DA: 10 PA: 66 MOZ Rank: 51

  • Catalyst Pharmaceuticals, Inc. (CPRX) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/CPRX

    WEBCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and...

    DA: 64 PA: 43 MOZ Rank: 58

  • Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely …

    yahoo.com

    https://finance.yahoo.com/news/catalyst-pharmaceuticals-inc-nasdaq-cprx-144905668.html

    WEB1 day ago · It would appear that 7.5% of Catalyst Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term ...

    DA: 27 PA: 78 MOZ Rank: 9

  • Catalyst Pharmaceuticals - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Catalyst_Pharmaceuticals

    WEBCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS).

    DA: 48 PA: 72 MOZ Rank: 9

  • Investors : Catalyst Pharmaceutical

    catalystpharma.com

    https://ir.catalystpharma.com/

    WEBCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.

    DA: 88 PA: 35 MOZ Rank: 81


  • About Catalyst: Our Mission, Our Values, Our Work

    catalystpharma.com

    https://catalystpharma.com/about-catalyst/

    WEBCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Our mission To improve the lives of patients with rare and ultra-rare diseases

    DA: 57 PA: 100 MOZ Rank: 92

  • Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full …

    yahoo.com

    https://finance.yahoo.com/news/catalyst-pharmaceuticals-reports-strong-fourth-230300728.html

    WEBFeb 28, 2024 · Catalyst Pharmaceuticals, Inc. Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022. Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an ...

    DA: 65 PA: 88 MOZ Rank: 33

  • Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® …

    catalystpharma.com

    https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fda-approval-agamreer

    WEBCORAL GABLES, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE ® (vamorolone) oral suspension 40 mg/mL for use in treating …

    DA: 99 PA: 14 MOZ Rank: 53

  • Catalyst Pharmaceuticals Announces FDA Acceptance of the

    globenewswire.com

    https://www.globenewswire.com/news-release/2023/10/13/2759920/0/en/Catalyst-Pharmaceuticals-Announces-FDA-Acceptance-of-the-Supplemental-New-Drug-Application-for-FIRDAPSE.html

    WEBOct 13, 2023 · U.S. FDA Assigned Target Action Date of June 4, 2024. CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced ...

    DA: 17 PA: 74 MOZ Rank: 50

  • Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year …

    catalystpharma.com

    https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-fourth-quarter-and-full-year

    WEBMar 16, 2022 · Total 2021 Revenues Increased Approximately 18% YoY to $141 Million. Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity. New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034. Actively Pursuing Opportunities to Diversify Commercial and …

    DA: 94 PA: 87 MOZ Rank: 69